Nucleus of the urate cluster. The held fabric carries serum uric acid (UA) mostly as a
marker that travels with cardiometabolic disease. This page holds the one interventional test of
whether it is a modifiable cause of blood pressure: a gold RCT meta-analysis showing that a
urate-lowering drug lowers BP. The finding is real but three boundaries keep it from settling the
causal question — the effect is on a surrogate (BP), not events; it is shown only in a
hyperuricemic stratum; and, decisively, the drug tested (allopurinol, a xanthine oxidase
inhibitor) has BP-lowering routes independent of urate-lowering itself, so the trials cannot say
whether the mediator is urate or the enzyme. Urate is a candidate lever, not a demonstrated one.
(inferred from Qu et al., 2016)
Update [2026-09-25]: the chain’s upstream leg — does dietary fructose raise urate? — is now
also held, and it is food-source-specific: sugar-sweetened beverages (SSBs) raise urate, 100%
fruit juice lowers it, whole fruit is null (§the upstream leg). The two legs come from different
research groups, but they are measured in different strata on different endpoints, so the joined
chain is still open. (inferred from Ayoub-Charette et al., 2021)
The effect — allopurinol lowers BP on the surrogate
Qu pooled 15 RCTs (per-study n 28-179) of urate-lowering therapy, overwhelmingly allopurinol (two febuxostat), in patients with hyperuricemia with or without hypertension; 13 trials reported BP. Effects are reported as standardized difference in means (SDM), a standardized effect, not mm Hg (Qu et al., 2016):
- SBP: SDM 0.321 (95% CI 0.145 to 0.497, p < 0.001), moderate heterogeneity (I2 = 42.0%).
- DBP: SDM 0.260 (95% CI 0.102 to 0.417, p = 0.001), low heterogeneity (I2 = 28.8%).
- Serum UA: SDM 1.548 (95% CI 0.840 to 2.256, p < 0.001) — the drug did lower the marker (I2 = 94.7%, high heterogeneity).
- Serum creatinine: SDM 0.312 (95% CI 0.008 to 0.615, p = 0.044), 5 trials, I2 = 0%.
Magnitude in absolute terms is not this MA’s to give. Qu reports SDM only. The one mm Hg anchor it cites is a prior MA (Agarwal 2013): SBP -3.3 mm Hg (95% CI 1.4 to 5.3), DBP -1.3 mm Hg (0.1 to 2.5) (Qu et al., 2016) — but that MA pooled longitudinal (non-RCT) studies, a weaker design, so the ~3 mm Hg figure is a borrowed, design-discounted anchor, not a value this RCT-MA established. A ~3 mm Hg SBP drop is small against the big BP levers -> Sodium Intake and Blood Pressure, Blood Pressure Lowering and Cardiovascular Events.
Subgroups — background antihypertensives and a dose paradox
- Works with and without background BP drugs. SBP fell both off medication (SDM 0.377, 95% CI 0.005 to 0.750, p = 0.047) and on it (SDM 0.295, 95% CI 0.097 to 0.492, p = 0.003); DBP likewise fell both off (SDM 0.426, 95% CI 0.122 to 0.729, p = 0.006) and on medication (SDM 0.167, 95% CI 0.003 to 0.331, p = 0.046) (Qu et al., 2016). (Qu’s abstract says the DBP effect was seen only with antihypertensives; the body forest-plot data show both subgroups significant — an internal inconsistency; the body data are the primary record and are used here.)
- Dose paradox — likely an artifact, not a knee. In patients on BP drugs, low-dose allopurinol (300 mg/day) reduced SBP (SDM 0.329, 95% CI 0.116 to 0.542, p = 0.002) while high-dose (>300 mg/day) did not (SDM 0.030, 95% CI -0.476 to 0.536, p = 0.908). Qu warns this rests on a single high-dose study with a CI spanning zero (Qu et al., 2016); it is a null from n=1, not evidence of an inverted dose-response, and should not be read as a plateau or upper bound -> The Underivable Optimum.
The marker-vs-mediator crux — is it urate, or the enzyme?
This is the payoff and the direct parallel to Inflammation as a Modifiable Lever’s CRP crux (the target is the pathway, not the marker molecule). Allopurinol lowers BP and lowers urate, so a naive read makes urate the mediator. But allopurinol is a xanthine oxidase inhibitor, and Qu reports that «some study has suggested that allopurinol itself may improve endothelial cell function and that the improvement is not related to lowering UA levels» (Qu et al., 2016). The trial set therefore cannot separate a urate-lowering effect from a xanthine-oxidase / vascular-oxidative-stress effect, and Qu says so at the outset: «It also remains unclear if a decrease in BP does occur, if it can be attributed to allopurinol itself or a decrease in UA level» (Qu et al., 2016).
What would resolve it (the design gap): a trial of a uricosuric — a drug that lowers urate without inhibiting xanthine oxidase — reaching the same BP effect would isolate urate as the mediator. Qu searched for uricosurics but the included evidence is essentially all XO-inhibitor, so the clean urate probe is missing. This is net-effect-not-intended at the mechanism level: the drug does more than lower the marker it was chosen for -> Net Effect vs Intended Effect.
Publication bias attenuates the SBP arm
Egger’s test showed significant funnel asymmetry for SBP (t = 2.03, one-tailed p = 0.032); trim-and-fill imputed three studies, after which the SBP effect was attenuated but remained significant (adjusted SDM 0.211, 95% CI 0.018 to 0.404). No publication bias was detected for DBP (Qu et al., 2016) -> Publication Bias and Selective Reporting.
What this does NOT license
- BP is a surrogate; events are untested here. Qu «only examined the effect of UA-lowering treatments on BP and serum creatinine and UA levels, and did not study cardiovascular or renal outcome such as incidence of cardiovascular events or CKD progression» (Qu et al., 2016). A urate-lowering -> BP-drop -> fewer-events chain is not shown; the surrogate-to-outcome leg stays an evidenced-target requirement, not an assumption -> Surrogate Outcomes. This is weaker than the inflammation lever, which has two RCTs on hard events with lipids unchanged.
- Hyperuricemic stratum only. The effect is established in patients with hyperuricemia; it does not transport to normouricemic people by evidence grade alone (the mechanism needs an elevated-urate support factor).
- A drug lever, not a lifestyle lever. This sizes the urate->BP link; it is not a recommendation to prescribe allopurinol for BP (a prescriber-zone act, out of scope), and Qu’s own cited Cochrane review found insufficient evidence to use urate-lowering therapy to treat hypertension (Qu et al., 2016).
The upstream leg — dietary fructose and urate: food source, not energy [2026-09-25, Ayoub-Charette 2021]
Does eating fructose raise serum urate? The upstream leg now has gold evidence, and the payoff is that fructose raises urate is not one exposure — the effect is carried by the food source, not by fructose-as-a-nutrient and not by energy control. Ayoub-Charette pooled 47 controlled feeding trials (85 comparisons, N=2763) across 9 food sources and 4 energy-control designs (substitution, addition, subtraction, ad libitum), in predominantly healthy, mixed-weight adults with baseline UA median ~4.6-5.5 mg/dL — roughly normouricemic, the complement to Qu’s hyperuricemic stratum; GRADE applied, minimally important difference for UA ±0.113 mg/dL. (Ayoub-Charette et al., 2021)
- Total fructose-containing sugars barely move urate, and only isocalorically. In substitution (isocaloric) trials total sugars raised UA by MD +0.16 mg/dL (95% CI 0.06-0.27, P=0.003); null in addition (+0.10, -0.07 to 0.27), subtraction (+0.09) and ad libitum (+0.19). GRADE very low for total sugars (double-downgrade for indirectness). The substitution effect is not fructose-general: SSBs carried 30.7% of the weight, and removing them collapsed it to +0.02 mg/dL (-0.07 to 0.1, NS). (Ayoub-Charette et al., 2021)
- SSBs raise urate — the one HIGH-certainty harm, and it persists at equal energy. SSB MD +0.42 mg/dL (0.24-0.59) in substitution and +0.43 (0.23-0.63) in addition, GRADE high in both. Because the substitution effect is isocaloric, SSB’s urate harm — unlike its body-weight harm, which is energy-mediated and vanishes on isoenergetic exchange -> Free Sugars Intake — does not dissolve at equal energy, pointing at fructose-specific metabolism rather than added calories. (Ayoub-Charette et al., 2021)
- 100% fruit juice LOWERS urate — also HIGH certainty. In addition trials 100% fruit juice MD -0.28 mg/dL (-0.43 to -0.13), GRADE high (upgraded for a significant dose-response). Sweets and desserts raised UA in substitution (+0.35, 0.07-0.63, moderate); a single chocolate addition trial lowered it (-0.38, -0.76-0.00, low). Whole fruit, dried fruit (raisins), sweetened dairy and added nutritive sweetener were null. Author’s bottom line: «This evidence is of high certainty, suggesting that the available evidence provides a reliable indication that SSBs increase and 100% fruit juice decreases uric acid», with the overall finding that «the effects of fructose-containing sugars on uric acid were more dependent on the food source than on energy control» (Ayoub-Charette et al., 2021).
Mechanism (directional, from the source’s own reasoning). Excess fructose drives an unregulated fructokinase pathway (ATP -> AMP -> urate) plus de novo purine synthesis; the source attributes the food-source split to the matrix and glycemic index — «SSBs do not offer many nutrients besides sugars, whereas other foods, like fruits, present sugars in a complex food matrix in which components like antioxidants, polyphenols, and so forth may counteract the negative effects of fructose», and «the food sources which increased uric acid all have a high glycemic index (GI), while food sources showing a reduction in uric acid have a lower GI». This is whole-organism, not the naive fructose dose-response -> Net Effect vs Intended Effect. (inferred from Ayoub-Charette et al., 2021)
Surrogate ladder — this leg stops at UA, not gout or BP. Uric acid is itself a surrogate: «High blood uric acid is a risk factor for gout, cardiovascular disease, and type 2 diabetes mellitus» (Ayoub-Charette et al., 2021), so the feeding trials move the marker, not a patient-important outcome -> Surrogate Outcomes. The source argues these results «appear to translate to gout risk» via its own cohort MA, which found «significant, positive associations of SSBs and fruit juice with the risk of gout, but no effect of fruit» — but note the food-source granularity trap it flags itself: that cohort MA grouped fruit drinks and 100% fruit juice together, so the fruit juice that raised gout risk is not the 100% fruit juice that lowered UA here. Fruit juice names two objects, and only 100% juice carries the urate-lowering signal -> Is the Food Category Doing Any Work. (Ayoub-Charette et al., 2021)
Why the wiki holds this — the fructose->urate->BP chain
The dietary relevance is the mediator leg of the fructose/uric-acid pathway that Free Sugars Intake flags (a pathway Te Morenga’s sugar->weight review treated as out of scope). Both legs are now held, from different research groups (a genuinely cross-group chain, not one lab’s story): the upstream food-source -> urate leg from Ayoub-Charette (Toronto 3D group), and the downstream urate -> BP leg from Qu (a separate Chinese group). Neither the two legs joined nor either alone closes the sugar decision:
- Upstream leg — now held (was a
[AWAITS]gap, closed 2026-09-25). Ayoub-Charette supplies gold evidence that the fructose -> urate leg is food-source-specific: SSBs raise urate (high), 100% fruit juice lowers it (high), whole/dried fruit and dairy null (§the upstream leg). So the actionable upstream lever is cut SSBs specifically, not cut fructose. - G-gap (the joined chain in the target stratum): no source runs food-source-fructose -> urate -> BP -> events end to end in one population. The upstream leg is measured on UA only in ~normouricemic healthy adults; the downstream leg on BP only in a hyperuricemic stratum on a drug. Whether cutting SSBs lowers BP (let alone events) in a normouricemic reasonably-healthy person — the wiki’s default stratum — remains untested. — a source carrying the whole chain, or the dietary-fructose -> BP arm directly.